Cases from Aug 2014 Cases from Aug 2014 Ryan Padrez & Patrick Peebles 9/10/14.

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

Respiratory Care in Children Better Care for Better Outcomes Dr Duncan Keeley GP Thame Thames Valley Strategic Clinical Network.
UTHSCSA Pediatric Resident Curriculum for the PICU ASTHMA IN THE PICU.
Use of Medications in Asthma Cyril Grum, M.D. Department of Internal Medicine *Based on the University of Michigan Guidelines for Clinic Care and the National.
STATUS ASTHMATICUS Sigrid Hahn, MD Andy Jagoda, MD, FACEP Department of Emergency Medicine Mount Sinai School of Medicine New York, New York.
Sept 2, 2014 VCU INTERNAL MEDICINE MORBIDITY AND MORTALITY.
ASTHMA Presented by your School Nurse.
AsthmaAsthma is a condition characterized by paroxysmal narrowing of the bronchial airways due to inflammation of the bronchi and contraction of the bronchial.
M ANAGING A CUTE A STHMA E XACERBATIONS Cathryn Caton, MD, MS.
Pediatric Respiratory Emergencies Part 2 Mohammed Al Faifi, MD. Pediatric Emergency Consultant Department of Emergency Medicine King Faisal Specialist.
Unit 5 SVN case studies By Elizabeth Kelley Buzbee AAS, RRT-NPS RCP.
Phamacology Final Exam Review.
Take a Deep Breath Asthma in Children Michael W. Peterson, M.D. Professor and Chief of Medicine UCSF Fresno.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Inpatient Asthma Sangeeta Schroeder, MD Resident Noon Conference.
Asthma What is Asthma ? V1.0 1997 Merck & ..
Drugs For Treating Asthma
Ibrahim Tawhari. Prepared by:. Scernario:  Khalid 14 years old come to the clinic c/o shortness of breath for one day duration.  He is a known asthmatic.
COPD Joshua Jewell. Epidemiology 8% of all individuals 10% age >40 6 th leading cause of death worldwide th in U.S. - >120,000 Expected 3 rd 2020.
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
Medications for the Acute Management of Asthma A. Shaun Rowe, Pharm.D., BCPS.
Childhood Asthma What is it? What does it look like? What can I do? Resources Tamra Green Peace College.
Paediatric Asthma 26 th November 2014 Julie Westwood Asthma Nurse Specialist RHSC
Asthma Mindy Remington Terri Kallal Peace College.
Diagnosing asthma History & Physical examination Measurements of lung function – Spirometry – Peak expiratory flow Measurements of airway hyperresponsiveness.
A STHMA By: Candace Murphy. W HAT I S A STHMA ? Asthma is a chronic disease. It affects the airways and makes breathing difficult. It causes an inflammation.
Respiratory Conditions and management in the CHOA ED P. Patrick Mularoni, MD.
Asthma Exacerbations Gil C. Grimes, MD Family Medicine.
Childhood Asthma A triad of atopic eczema, allergic rhinitis and asthma is called atopy.[53] The strongest risk factor for developing asthma is a history.
Asthma Medications ESAT 4001 Pharmacology in Athletic Training.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
1 Asthma October 30, Weiss, Gergen, & Hodgson (1992)2 Pediatric Statistics Prevalence increasing School absences Estimated as more than 10 million.
NYU Medical Grand Rounds Clinical Vignette Verity Schaye, MD PGY-3 September 15, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Asthma A Presentation on Asthma Management and Prevention.
Diagnosing and Staging Asthma*
Update Presented by: Katy Zahner BSN, RN, CCRN Georgetown University Nurse Educator Student.
AUGUST 6, 2010 Morning Report. Pneumonia Risk Factors  Cold months  Cigarette or wood stove smoke  Low socioeconomic status  Boys  Underlying.
Advances in Pediatric Asthma Care Keyvan Rafei, MD, MBA Division Head, Pediatric Emergency Medicine Chairman, Pediatric Asthma Program.
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
بسم الله الرحمن الرحيم وَإِذَا مَرِضْتُ فَهُوَ يَشْفِينِ صدق الله العظيم الشعراء 80.
Helmi Lubis, dr, SpAK Ridwan M. Daulay, dr, SpAK Wisman Dalimunthe, dr, SpA Rini S. Daulay, dr, M.Ked(Ped), SpA.
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
ASTHMA Definition: Asthma is a chronic lung disease due to inflammation of the airways resulted into airway obstruction. The obstruction is reversible.
Management Of Asthma With Acute Exacerbation In Pediatric Patients Speaker : Dr. Meng-Shu Wu.
Breathing Easier. What is asthma? A chronic disease The lining of the airway becomes inflamed and swells. Mucus can build up. The swelling and mucus makes.
Wheeze and Asthma Key Facts and Updates Dr Reena Bhatt, Paediatric Darzi Fellow in Asthma.
Foundations of Interprofessional Collaboration (FIPC): An Introduction to TeamSTEPPS® LEVEL 3 Overview of Clinical Management of Anaphylaxis for Nursing.
Eileen G. Holland, Pharm.D., BCPS Associate Professor
Asthma in the child Dr A Rahman GPST3.
Respiratory disorders
Evaluation and Treatment of Children with Bronchiolitis in the Emergency Department Suspected bronchiolitis: Otherwise healthy child < 24 months of age.
Foundations of Interprofessional Collaboration (FIPC): An Introduction to TeamSTEPPS® LEVEL 3 Overview of Clinical Management of Anaphylaxis for Medicine.
Foundations of Interprofessional Collaboration (FIPC): An Introduction to TeamSTEPPS® LEVEL 3 Overview of Clinical Management of Anaphylaxis for Respiratory.
Bronchial Asthma Dr.Radhakrishna. S. A. Bronchial Asthma Dr.Radhakrishna. S. A.
APPROACH TO A PATIENT WITH ACUTE SEVERE ASTHMA
Evaluation and Treatment of Children with Bronchiolitis in the Emergency Department Suspected bronchiolitis: Otherwise healthy child < 24 months of age.
Asthma in the pediatric population
Pediatrics On-Call Michael Dale Warren, MD Pediatric Chief Resident
ACUTE INTERVENTION IN < 10 SLIDES! 1/25/2017
Asthma in the pediatric population
Respiratory disorders
Drugs Affecting the Respiratory System
ASTHMA Dr. Saviour K. Assoah (Medicine Dept). OUTLINE Definition Epidemiology Risks / precipitating factors Symptoms and signs Pathophysiology Types of.
Presentation transcript:

Cases from Aug 2014 Cases from Aug 2014 Ryan Padrez & Patrick Peebles 9/10/14

 Discussion of Cases Status Asthmaticus

 What is Asthma? 1. Airway obstruction  Bronchoconstriction  Inflammation 2. Reversible  Improves in response to bronchodilators 3. Recurrent  Triggers: Infection, stress, allergens, exercise, cold, foods, smells, etc

 Inhaled beta-agonists: Albuterol  Safe and well-tolerated in kids  HR up to 200 commonly seen  Intermittent albuterol (MDI and nebulizer)  Peak activity at 30 minutes  Dosing: 0.15mg/kg/dose– titrate to effect  Continuous albuterol  Starting dose: 0.5mg/kg/hour (or 5-15 mg/hour)  May go up as tolerated

 Ipratropium bromide (Atrovent)  Anticholinergic  Bronchodilation and decreased secretions  No cardiovascular side effects, very cheap  RCT’s of albuterol/atrovent vs albuterol alone  Clinical improvement  Decreased hospitalization  Especially most severe  Dosing: 3 doses initially, q6h after that  No evidence for continued benefit after first 3 doses

 Steroids  Systemic: short burst (3-5 days)  Prevent hospitalization, reduce duration of symptoms  Most effective when given early in exacerbation  IV/IM equivalent to PO  Options  Solumedrol/prednisone 1-2mg/kg/dose (max 60mg)  Dexamethasone 0.6mg/kg/day  Of note: no established role of inhaled steroids in acute exacerbation

 Zemek (2012): 644 kids >2, before and after protocol for nurse-initiated steroids in triage: 19% 11.7% 72 min 28 min Zemek, Pediatrics, March 2012

 Management of Status Asthmaticus in ED (or 6M Urgent Care) Case #1

  CC: 18mo boy with history of RAD with viral illnesses presents to ER with increased work of breathing  HPI: 1 day viral URI symptoms, tactile fevers, stuffy nose; difficulty breathing overnight, fussy and poor PO intake in the morning, parents brought into ER at 8am on 8/31  Meds: none All: NKDA  PMH: as noted, immunizations up to date until 1yo  Social History: intact family  Family History: mom +allergies/asthma Case #1: 18mo with RAD

  Initial Exam in ER:  T: 37.1, P 170, RR 50-60, O2 sat 85% on RA.  Gen: nasal flaring, obvious respiratory distress, somnolent  Lungs: Supra-clavicular, intercostal, subcostal retractions, scattered expiratory wheezes  Brought to Zone 1, Bed 4 and a Zone 1 ED resident assigned to case Case #1: 18mo with RAD

  8:28am: Neb x1 (albuterol + ipratropium bromide)  8:47am: Neb x2 (albuterol + ipratropium bromide)  9am re-assessment by nurse :  T 37.1, P 178, RR 48, O2 sat 98% RA  VBG: 7.18/49/32/-10 and Lactate 2.5  ~9am: IV Dexamethasone x1 + IV fluids 20ml/kg NS bolus  ~9:30: Neb x3 (albuterol + ipratropium bromide)  10am: repeat labs and CXR  VBG: 7.27/35/70/-10  CBC: 9.9>38.3<234  Chem: 143/4.0/113/12/11/0.22  CXR: no abnormalities  Peds Chief Resident assessment at ~10am:  Reactive to exam but not crying and not verbally interactive, sleepy, obvious respiratory distress, nasal flaring, retractions with faint wheezing  What was done well and what could be different at this point in time? Case #1: ED Management

 Asthma Algorithm

 Case#1: Continued  To Recap:  ~1 hr 20 min the team gave albuterol/atrovent X3, IV dexamethasone, IV fluid bolus  RR 40-50, HR180s, O2 sat 98% on facemask  Gen: looks sleepy, tachypnea with flaring and retractions, not very verbal  Lungs: faint wheezing  What does this child have? Status Asthmaticus  ED team asks peds team if next steps are to give:  More IV fluids and IV Mag Discussion Question: What could be done to optimize management if we think child has status asthmaticus?

 Status Asthmaticus  Status Asthmaticus definition: “unresponsive to inhaled bronchodilators”  Next steps if concerned for status asthmaticus:  Maximize O2 delivery  Move to continuous bronchodilator  Get IV access  Consider dose of IV steroids What if none of these things work???

  Magnesium  Epinephrine  Terbutaline 2 nd Line Medications

 Evidence: Magnesium  Bronchodilation via SM relaxation  Single IV dose:  RCT data in children has established safety and efficacy  Most beneficial in severe asthmaticus  Repeated doses: utility unclear  Must be infused over 20 minutes  Adverse effects: flushing, nausea, hypotension

 Epinephrine  Easily available!  Found on code cart, easy to dose  Fastest absorption when IM, in lateral thigh  Previously standard of therapy, now less favorable due to cardiac effects

 Evidence: Terbutaline  IV beta-agonist,  Less B2-selective than albuterol  Efficacy: no consistent decrease in symptoms or length of stay shown  Recent trials: trend toward improvement?  Minor side effects common  Can be given SC or IV  Loading dose of 10 mcg/kg SC or IV  Infusion of 0.4mcg/kg/min

 Recommendations: Systemic Bronchodilators  Magnesium first-line systemic bronchodilator, for pediatric status asthmaticus  Consider terbutaline as second-line agents  IM Epinephrine if no others available

  In ED Peds Team Ordered:  Continuous Albuterol at 20mg/hr  IV solumedrol  IV magnesium sulfate 40mg/kg x1  IV bolus of fluids #3 followed by 1x maintenance  Admit to 4E (after mag, patient began to look better, crying, better air movement, more prominent wheezing) Back to Case

  For ED Management of Severe Asthma  Ensure systemic steroids given <1 hour  consider IV route if severe presentation  Duo-nebs x3 with poor response move to continuous nebulized albuterol and can start 5-15mg/hr and titrate up to effect  Get IV access early  IV magnesium the most effective systemic bronchodilator for status asthmaticus Key Points for Case #1

 Discussion Question Should we change our asthma algorithm to include continuous albuterol for “severe” classification?

  Only RCT included  Only in ED  “Continuous” can mean 1 neb q15m or >4 nebs in 1 hr

  Admission to hospital reduced in continuous group  Patients with “severe” asthma scores benefited most from continuous  Side effects of albuterol were the same in both groups

 UCSF Asthma Algorithm

 Management of Status Asthmaticus in 4E ICU Case #2

  ID: 11yo M with history of asthma on Qvar with very poor compliance presents to ED with significant increased work of breathing.  HPI: normal state of health, but recently moved in with father in SF x1 week with cats and cigarette smoke in home; coupled with poor compliance with Qvar (ICS controller). Brought to ER by ambulance. In route received two albuterol nebs by EMS.  Meds: Qvar, singulair, albuterol PRN All: NKDA  PMH: multiple admissions for asthma, no intubations, immunizations UTD  Family History: 2 family members with asthma Case #2: 11yo M with Severe Asthma

  Exam ( s/p 2 nebs in ambulance)  Vitals: RR 40-50, O2 sats 92% room air  Gen: tripod position, significant respiratory distress, 2-3 word sentences  Lungs: retractions prominent, decreased air movement  ED Management:  Continuous albuterol 10mg/hr with 100% O2 face mask  IM Epi x1  IV solumedrol  IV Mag x1  Repeat IM Epi  VBG: 7.3/52/-0.8  CXR: no focal infiltrate  Admitted to 4E ICU with “status asthmaticus” Case #2: In ED

  Pediatric Team Management:  Continue albuterol 20mg/hr  HFNC 20L/min  IV solumedrol q6h  IVF at maintenance Case #2: In ICU

 Respiratory Therapy Teaching Different devices to provide O2 support on 4E vs 6A vs 6M Different ways to deliver continuous albuterol Optimal flow rate when giving albuterol with HFNC

  Pediatric Team Management:  Continue albuterol 20mg/hr  HFNC 20L/min  IV solumedrol q6h  IVF at maintenance Case #2: In ICU

  Continuous albuterol neb ran out in early morning hours for uncertain amount of time  Significant respiratory distress resulting in:  Epi #3 IM given  IV Mag #2 given  Continuous Albuterol 20mg/hr neb with HFNC Discussion Question: What system issues that may have lead to this error? Case #2: In ICU

  Hospital Night #2:  Overnight peds team weaned from 20mg/hr continuous albuterol to 15mg/hr  In AM worsening respiratory distress and increased expiratory wheezes  Team elected to increase albuterol back to 20mg/hr Discussion Question : Was this patient weaned too quickly? What resources or metrics can we use to guide our weaning management? Back to Case#2: In ICU

 Kelly CS, Andersen CL, Pestian JP. Improved outcomes for hospitalized asthmatic children using a clinical pathway. Ann Allergy Asthma Immunol. 2000;84(5):509–516. et al.

 Review of Key Points  Inhaled bronchodilators are first line agent in mild, mod and severe asthma  Use aggressively, including moving to continuous early  Start steroids early <1 hr  Magnesium is the most beneficial systemic bronchodilator in status asthmaticus  Consider systematic approach to weaning

 Evidence: Theophylline  Methylxanthine (related to caffeine)  Fallen out of favor due to fear of toxicity, need for monitoring  Efficacy:  2005 meta-analysis: improved lung function, but did not reduce symptoms or length of stay  2005 RCT: more cost-effective than terbutaline